5 results about "Pathophysiology" patented technology

This invention relates to the field of medical image processing technology, specifically to an automatic detection and classification method and system for intracranial hemorrhage based on three-window CT fusion and label-dependent graph neural network, including the following steps: S100, acquiring the original CT slice image of the head to be detected, performing grayscale mapping on the original slice image based on preset brain window, subdural window and bone window respectively, and stacking the three mapped images along the channel dimension to generate a three-channel fused image; This invention greatly enriches the model's global perception ability of multi-level physiological structures such as brain parenchyma, microhematomas and skull lesions through innovative three-window physical mapping and channel fusion; it introduces a hybrid adjacency matrix graph neural network that combines prior knowledge of neuroradiology with data-driven approach, explicitly establishing pathophysiological causal relationships between various hemorrhage subtypes at the model architecture level, effectively eliminating logical contradictions in predictions that violate clinical common sense.

Provided herein include compounds, compositions, kits and methods for preventing and treating psychiatric disorders. The composition and methods described herein can prophylactically treat a subject prior to and / or after a stressor and / or prior to the recurrence of a stressor, thereby preventing or delaying a relapse of depression or depression-like and / or stress-induced behaviors and disorders. The composition can comprise a serotonin 4 receptor (S-HUR) agonist and an N- methyl-D-aspartate (NMDAR) antagonist and a pharmaceutically acceptable salt, analog, derivative or metabolite thereof.

This model helps in understanding the gross anatomy (shape, relative size, and three-dimensional positional relationship) of the intestines and mesentery. It is useful for medical students and young healthcare professionals to acquire basic knowledge for understanding the pathophysiology of diseases and injuries of abdominal organs, as well as for examination and treatment. [Solution] The model 50 has an intestinal tract 2 covered and embedded by the peritoneum 1, an intestinal tract 2 provided in the posterior abdominal wall 4 in a form where much of the outer circumference is covered by the peritoneum 1, and an intestinal tract 2 provided in the posterior abdominal wall 4 via the mesentery 5, wherein each of the intestinal tracts 2 is made of a flexible and smooth pliable material and attached to a substrate 23 which is the posterior abdominal wall 4, and each of the intestinal tracts 2 and the mesentery 5 are configured to be the same as or approximately the same length and thickness as those in living organisms, thereby solving the above problem.

Pharmaceutical compositions are described, comprising (CAR-HNE), i.e. a molecule obtained from carnosine and 4-hydroxy-2-nonenal, for the prevention and / or treatment of ophthalmic diseases resulting from an imbalance of the redox equilibria in ocular cells and tissues. A chemical conjugate HA-CAR-HNE obtained from hyaluronic acid (HA), carnosine (CAR), and hydroxynonenal (HNE), the synthesis process, and its use as such or in pharmaceutical compositions for the prevention and / or treatment of diseases related to oxidative stress, whose pathophysiology is linked to an imbalance of redox equilibria in cells and tissues, are also described.

OF THE INVENTION SEROLOGICAL MARKER FOR THE LATENT FORM OF TOXOPLASMOSIS In the present invention, inventors screened the bradyzoite proteome for immunogenic protein candidates in an unbiased manner and identified the Bradyzoite Serological Marker (BSM) as a second serological biomarker for Toxoplasma chronicity in mice. BSM serology correctly distinguishes cyst-bearing mice with a sensitivity and specificity of 97.96% (IC95: 89.31 - 99.90) and 100.0% (IC95: 86.20 - 100.0) respectively. In humans, both bradyzoite markers BCLA and BSM are in moderate agreement (kappa=0.308) and BSM serology is unexpectedly positive in 30% of patients with past immunity, raising many questions. Nevertheless, bradyzoite serology could provide new reference standards for studying the pathophysiology of chronic toxoplasmosis in humans, especially cyst carriage, which has been poorly described. Thus the invention relates to a new Toxoplasma gondii protein, hereafter referred as BSM, a new serological marker whose expression is restricted to the latent form of Toxoplasmosis (bradyzoite / cyst).